Gene transfer therapy by either type 1 or type 2 adeno-associated virus expressing human prostaglandin I2 synthase gene is effective for treatment of pulmonary arterial hypertension

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 1, 2013, Pages 54-59

  Kataoka, Masaharu ^a,b   Kawakami, Takashi ^a   Tamura, Yuichi ^a   Yoshino, Hideaki ^b   Satoh, Toru ^b   Tanabe, Tadashi ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adeno associated virus; gene transfer; prostaglandin I2 synthase; pulmonary arterial hypertension

Indexed keywords

PARVOVIRUS VECTOR; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL WALL; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HEART LEFT VENTRICLE; HYPOXIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; SEROTYPE; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DEPENDOVIRUS; GENETIC THERAPY; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, INBRED C57BL; PULMONARY ARTERY; SYSTOLE;

EID: 84871547615     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412457046     Document Type: Article

References (25)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 ; 107 (2). 216-223
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 ; 115 (5). 343-349
3. Rich S.. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest. 1998 ; 114 (3 suppl). 237S - 241S
4. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress.". Circulation. 2000 ; 102 (22). 2781-2791
5. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 ; 263 (5579). 663-665
6. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979 ; 300 (20). 1142-1147
7. Nagaya N, Yokoyama C, Kyotani S, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation. 2000 ; 102 (16). 2005-2010
8. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999 ; 34 (4). 1184-1187
9. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984 ; 1 (8385). 1046-1047
10. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990 ; 112 (7). 485-491
11. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993 ; 70 (4). 366-370
12. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 ; 121 (6). 409-415
13. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 ; 334 (5). 296-302
14. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 ; 338 (5). 273-277
15. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002 ; 106 (12). 1477-1482
16. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40 (4). 780-788
17. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997 ; 349 (9062). 1365
18. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999 ; 34 (4). 1188-1192
19. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 ; 347 (5). 322-329
20. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med. 2002 ; 165 (6). 800-804
21. Kawakami T, Kanazawa H, Satoh T, et al. AAV-PGIS gene transfer improves hypoxia-induced pulmonary hypertension in mice. Biochem Biophys Res Commun. 2007 ; 363 (3). 656-661
22. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006 ; 12 (3). 342-347
23. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998 ; 351 (9117). 1702-1703
24. During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther. 2001 ; 12 (12). 1589-1591
25. Kataoka M, Nagaya N, Satoh T, et al. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med. 2005 ; 172 (12). 1575-1580